title: Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers.
abstract: Calcineurin inhibitors improve kidney allograft survival in the posttransplantation period; however, they may cause nephrotoxicity. The objective of this study was to compare the effect of cyclosporine (CsA) and tacrolimus (Tac) treatment on the transplanted kidney. The study included 219 patients aged 21 to 65 years. Of these, 120 (39 women and 81 men) were treated with CsA and 99 (38 women and 61 men) were treated with Tac. Patients were divided into 4 groups depending on the time since kidney transplantation. We evaluated urine markers of nephrotoxicity: proximal tubular cells lysosomal enzymes (N-acetyl-beta-d-glucosaminidase [NAG] and its isoform NAG-B, beta-d-galactosidase, and beta-glucouronidase) and brush border enzymes (alanyl aminopeptidase and gamma-glutamyl transpeptidase). Urine activities of nephrotoxicity markers were compared in CsA- and Tac-treated patients groups depending on the duration of treatment and allograft function as measured by serum creatinine concentration. Correlation studies between CsA and Tac levels and enzyme activities were performed in both groups and in the entire patient cohort. NAG and its isoform NAG-B seemed to be the most reliable markers of nephrotoxicity. Despite the significant correlation between NAG urine activity and serum creatinine concentration in the CsA group, there were no significant differences in NAG or NAG-B activities between CsA- and Tac-treated graft recipients.
authors: Department of Toxicology, Laboratory of Environmental Nephrotoxicity Markers, Wroclaw Medical University, Wroclaw, Poland. zomar@tox.am.wroc.pl
authors: Z
authors: Z
authors: Marchewka
authors: J
authors: J
authors: Kuźniar
authors: M
authors: M
authors: Zynek-Litwin
authors: K
authors: K
authors: Falkiewicz
authors: B
authors: B
authors: Szymańska
authors: A
authors: A
authors: Roszkowska
authors: M
authors: M
authors: Klinger
mesh_terms: D000118:Acetylglucosaminidase / Q000097:blood; D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D007687:Kidney Tubules, Proximal / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D055815:Young Adult; D001616:beta-Galactosidase / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001616:beta-Galactosidase; D000118:Acetylglucosaminidase; D016559:Tacrolimus